|
|
Post by yash on Jun 2, 2020 21:53:19 GMT -5
|
|
|
|
Post by Clement on Jun 3, 2020 6:52:06 GMT -5
longer term - dry powder shorter term - mist by means of nebulizer "Company executives have told Wall Street analysts that in the longer term, Gilead is exploring dry powder versions to be inhaled as well as a formulation that is injected under the skin. It won't take the shape of a pill because its chemical makeup would degrade in the liver. In the short term, Gilead is studying how its existing intravenous formulation can be diluted so it can be used with a device that'll administer it as a mist inhaled into the lungs. The coronavirus attacks the lungs, and the nebulizer would make remdesivir more directly available to the upper airway and lung tissue. This would allow patients who are not hospitalized to get early treatment." |
|
|
|
Post by itellthefuture777 on Jun 3, 2020 8:53:58 GMT -5
Would explain the silence..
|
|
|
|
Post by peppy on Jun 3, 2020 16:02:13 GMT -5
longer term - dry powder shorter term - mist by means of nebulizer " Company executives have told Wall Street analysts that in the longer term, Gilead is exploring dry powder versions to be inhaled as well as a formulation that is injected under the skin. It won't take the shape of a pill because its chemical makeup would degrade in the liver. In the short term, Gilead is studying how its existing intravenous formulation can be diluted so it can be used with a device that'll administer it as a mist inhaled into the lungs. The coronavirus attacks the lungs, and the nebulizer would make remdesivir more directly available to the upper airway and lung tissue. This would allow patients who are not hospitalized to get early treatment." there it is. however, it was determined it was too much medication for technosphere? It would take many cartridges to dose? Is this the case? |
|
|
|
Post by lennymnkd on Jun 3, 2020 17:33:02 GMT -5
Is this the one ( remdesiver ) mike gave up on ?
|
|
|
|
Post by rfogel on Jun 3, 2020 18:52:34 GMT -5
Is this the one ( remdesiver ) mike gave up on ? I recall someone here posted that the amount required for each dose would require like a hundred inhalations, so Mannkind opted out. |
|
|
|
Post by goyocafe on Jun 3, 2020 18:57:28 GMT -5
 Never enough information to ever really know; which drug, when, who?
|
|
|
|
Post by mango on Jun 3, 2020 22:11:46 GMT -5
Is this the one ( remdesiver ) mike gave up on ? I recall someone here posted that the amount required for each dose would require like a hundred inhalations, so Mannkind opted out. I do not recall MannKind ever mentioning Remdesiver. Can you provide a source and/or a direct quote of this by the Company stating they were working on Remdesiver and found it would require "a hundred inhalations" and so they gave up? |
|
|
|
Post by mnkdfann on Jun 3, 2020 23:37:15 GMT -5
These comments may be what some are thinking / talking about: mnkd.proboards.com/post/206063"I think the dose for each inhalation is only about 1mg (could have increased slightly lately), and Remdesivir requires 100mg/day. Even if a 75% smaller dose is required due to administration by inhalation, that is still a lot of puffs..." "Mike did mention on the Q1 CC that they considered and rejected a drug because of dosage issues, and the number of inhalations he mentioned lines up with this. So while he did not mention the drug name, I believe he was talking about Remdesivir." seekingalpha.com/article/4343933-mannkind-corporations-mnkd-ceo-michael-castagna-on-q1-2020-results-earnings-call-transcript?part=singleMike C: "In terms of developing treatments for COVID-19, we evaluated four opportunities that I talked about recently. At this point, we decided not pursuing two of them one because it's likely an OTC product, that we won't be able to move forward in our current capacity or FDA regulations. And the second one is, because it would require probably 10 to 15 cartridges of inhalation powder, three to four times a day, which just is not a feasible solution." |
|
|
|
Post by mango on Jun 4, 2020 7:16:19 GMT -5
Mike was referring to Immix's drugs.
|
|
|
|
Post by agedhippie on Jun 4, 2020 8:19:37 GMT -5
Mike was referring to Immix's drugs. The second one of the two does sound like Remdesivir though. Not that it really matter since dry powder inhalers are a commodity item. |
|
|
|
Post by peppy on Jun 4, 2020 8:47:35 GMT -5
Mike was referring to Immix's drugs. The second one of the two does sound like Remdesivir though. Not that it really matter since dry powder inhalers are a commodity item.Aged, are there other FDA approved dry powder inhalers capable of taking the medication to the alveolar beds? Do tell.  Don't make me post the circuit. |
|
|
|
Post by mango on Jun 4, 2020 8:50:37 GMT -5
Mike was referring to Immix's drugs. The second one of the two does sound like Remdesivir though. Not that it really matter since dry powder inhalers are a commodity item. He wasn't referring to Remdesivir, he was referring to the two (out of four) potential drugs with Immix. |
|
|
|
Post by peppy on Jun 4, 2020 9:10:27 GMT -5
The second one of the two does sound like Remdesivir though. Not that it really matter since dry powder inhalers are a commodity item. He wasn't referring to Remdesivir, he was referring to the two (out of four) potential drugs with Immix. ok, good that changes everything. If Gilead is looking at MNKD, word will get out, and we will see it in volume... no sign yet.  |
|
|
|
Post by mango on Jun 4, 2020 9:23:18 GMT -5
He wasn't referring to Remdesivir, he was referring to the two (out of four) potential drugs with Immix. ok, good that changes everything. If Gilead is looking at MNKD, word will get out, and we will see it in volume... no sign yet. Kowtow I hear GILD is looking for a dry powder inhalation system for Remdesivir. I think I found the solution: MannKind’s inhalation devices utilize the concept of flow resistance. MannKind delivers their dry powders slower than anyone else in the world. This enables the dry powder to properly navigate the anatomical airways down to the deep lung with minimal deposition on the back of the throat. The powder fully traverses from the cartridge to the deep lung in the first 500 milliseconds of inhalation and only requires about 350-500mL of air. The inhalation device and powder creates synergy. This explains some of why they are so effective and successful together. ~70% of the inhalation powder is delivered to the lungs. MannKind's inhalation devices are a marvel of engineering. |
|
Never enough information to ever really know; which drug, when, who? 
